Nasal potential difference measurements in diagnosis of cystic fibrosis: An international survey

Journal of Cystic Fibrosis

Volumn 13, Issue 1, 2014, Pages 24-28

  Naehrlich, Lutz ^a   Ballmann, Manfred ^b   Davies, Jane ^c,d   Derichs, Nico ^e   Gonska, Tanja ^f   Hjelte, Lena ^g   van Konigsbruggen Rietschel, Silke ^h   Leal, Teresinha ⁱ   Melotti, Paola ^j   Middleton, Peter ^k   Tümmler, Burkhard ^l   Vermeulen, Francois ^m   Wilschanski, Michael ⁿ  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

^c ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f HOSPITAL FOR SICK CHILDREN   (Canada)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h UNIVERSITY OF COLOGNE   (Germany)

ⁱ UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^j UNIVERSITY HOSPITAL OF VERONA   (Italy)

^k UNIVERSITY OF SYDNEY   (Australia)

^l HANNOVER MEDICAL SCHOOL   (Germany)

^m UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁿ HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

more..

Author keywords

Cystic fibrosis; Diagnosis; Nasal potential difference

Indexed keywords

AMILORIDE; CHLORIDE; ISOPRENALINE;

ARTICLE; AUSTRALIA; BELGIUM; CANADA; CYSTIC FIBROSIS; DIAGNOSTIC TEST; FRANCE; GENOTYPE; GERMANY; NASAL POTENTIAL DIFFERENCE; POTENTIAL DIFFERENCE; QUESTIONNAIRE; REFERENCE VALUE; UNITED KINGDOM; VALIDATION STUDY;

CYSTIC FIBROSIS; DIAGNOSIS; NASAL POTENTIAL DIFFERENCE;

ADRENERGIC BETA-AGONISTS; AMILORIDE; CHLORIDES; CYSTIC FIBROSIS; DIAGNOSTIC TECHNIQUES, RESPIRATORY SYSTEM; ELECTRODIAGNOSIS; EPITHELIAL SODIUM CHANNEL BLOCKERS; EUROPE; HEALTH CARE SURVEYS; HUMANS; INTERNATIONALITY; ISOPROTERENOL; MEMBRANE POTENTIALS; NASAL MUCOSA; OBSERVER VARIATION; QUESTIONNAIRES; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS;

EID: 84890429584     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2013.08.006     Document Type: Article

References (30)

1. Knowles M., Gatzy J., Boucher R. Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N Engl J Med 1981, 305:1489-1495.
2. Alton E.W., Currie D., Logan-Sinclair R., Warner J.O., Hodson M.E., Geddes D.M. Nasal potential difference: a clinical diagnostic test for cystic fibrosis. Eur Respir J 1990, 3:922-926.
3. Knowles M.R., Paradiso A.M., Boucher R.C. In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 1995, 6:445-455.
4. Sauder R.A., Chesrown S.E., Loughlin G.M. Clinical application of transepithelial potential difference measurements in cystic fibrosis. J Pediatr 1987, 111:353-358.
5. Middleton P.G., Geddes D.M., Alton E.W. Protocols for in vivo measurement of the ion transport defects in cystic fibrosis nasal epithelium. Eur Respir J 1994, 7:2050-2056.
6. Rosenstein B.J., Cutting G.R. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr 1998, 132:589-595.
7. Schuler D., Sermet-Gaudelus I., Wilschanski M., Ballmann M., Dechaux M., Edelman A., et al. Basic protocol for transepithelial nasal potential difference measurements. J Cyst Fibros 2004, 3(Suppl. 2):151-155.
8. Hofmann T., Bohmer O., Huls G., Terbrack H.G., Bittner P., Klingmuller V., et al. Conventional and modified nasal potential-difference measurement in cystic fibrosis. Am J Respir Crit Care Med 1997, 155:1908-1913.
9. Ahrens R.C., Standaert T.A., Launspach J., Han S.M., Teresi M.E., Aitken M.L., et al. Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis. Pediatr Pulmonol 2002, 33:142-150.
10. Naehrlich L., Bagheri-Behrouzi A. Misdiagnosis of cystic fibrosis: experience from Germany. J Cyst Fibros 2013, 12:68-73.
11. Standaert T.A., Boitano L., Emerson J., Milgram L.J., Konstan M.W., Hunter J., et al. Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials. Pediatr Pulmonol 2004, 37:385-392.
12. Rowe S.M., Clancy J.P., Wilschanski M. Nasal potential difference measurements to assess CFTR ion channel activity. Methods Mol Biol 2011, 741:69-86.
13. De Boeck K., Kent L., Davies J., Derichs N., Amaral M., Rowe S.M., et al. CFTR biomarkers: time for promotion to surrogate end-point. Eur Respir J 2013, 41:203-216.
14. De Boeck K., Wilschanski M., Castellani C., Taylor C., Cuppens H., Dodge J., et al. Cystic fibrosis: terminology and diagnostic algorithms. Thorax 2006, 61:627-635.
15. Farrell P.M., Rosenstein B.J., White T.B., Accurso F.J., Castellani C., Cutting G.R., et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008, 153:S4-S14.
16. Ooi C.Y., Dupuis A., Ellis L., Jarvi K., Martin S., Gonska T., et al. Comparing the American and European diagnostic guidelines for cystic fibrosis: same disease, different language?. Thorax 2012, 67:618-624.
17. von Eye A. An alternative to Cohen's κ. Eur Psychol 2006, 11:12-24.
18. Fleiss J. Statistical methods for rates and proportions 1981, Wiley, New York. 2nd ed.
19. Vivani L., Zolin A., Olesen H., van Rens J., Iansa P., Fox A., et al. ECFSPR Annual Report 2008-2009 2012, [updated 10.05.2013; Available from: http://www.ecfs.eu/files/webfm/webfiles/File/ecfs_registry/ECFSPR_Report0809_v32012.pdf].
20. Cystic Fibrosis Australia Cystic fibrosis in Australia 2009 - 12th annual report from the Australian Cystic Fibrosis Data Registry 2011, [Available from: http://www.cysticfibrosis.org.au/media/wysiwyg/CF-Australia/PDF_files/Cystic_Fibrosis_in_Australia_2009.pdf].
21. Cystic Fibrosis Canada Canadian Cystic Fibrosis Registry 2011 Annual Report 2013, [updated 10.05.2013; Available from: http://www.cysticfibrosis.ca/assets/files/pdf/Registry2011FINALOnlineEN.pdf].
22. Wilschanski M., Famini H., Strauss-Liviatan N., Rivlin J., Balu H., Bibi H., et al. Nasal potential difference measurements in patients with atypical cystic fibrosis. Eur Respir J 2001, 17:1208-1215.
23. Sermet-Gaudelus I., Girodon E., Sands D., Stremmler N., Vavrova V., Deneuville E., et al. Clinical phenotype and genotype of children with borderline sweat test and abnormal nasal epithelial chloride transport. Am J Respir Crit Care Med 2010, 182:929-936.
24. Middleton P.G., House H.H. Measurement of airway ion transport assists the diagnosis of cystic fibrosis. Pediatr Pulmonol 2010, 45:789-795.
25. Green A., Kirk J. Guidelines for the performance of the sweat test for the diagnosis of cystic fibrosis. Ann Clin Biochem 2007, 44:25-34.
26. Bronsveld I., Vermeulen F., Sands D., Leal T., Leonard A., Melotti P., et al. Influence of perfusate temperature on nasal potential difference. Eur Respir J 2013, 42:371-379.
27. Vermeulen F., Proesmans M., Feyaerts N., De Boeck K. Nasal potential measurements on the nasal floor and under the inferior turbinate: does it matter?. Pediatr Pulmonol 2011, 46:145-152.
28. De Boeck K., Derichs N., Fajac I., de Jonge H.R., Bronsveld I., Sermet I., et al. New clinical diagnostic procedures for cystic fibrosis in Europe. J Cyst Fibros 2011, 10(Suppl. 2):S53-S66.
29. Liu B., Hathorne H., Hill A., Cohen M., Beamer J., Solomon M.G., et al. Normative values and receiver operating characteristics of NPD for diagnostic measurements. Pediatr Pulmonol 2010, 303:307. [Abstract].
30. Leonard A., Lubamba B., Dhooge B., Noel S., Wallemcq P., Lebecque P., et al. Comparative variability of nasal potential difference measurements in human and mice. Open J Respir Dis 2012, 2:43-56.